JP2018004657A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018004657A5 JP2018004657A5 JP2017175482A JP2017175482A JP2018004657A5 JP 2018004657 A5 JP2018004657 A5 JP 2018004657A5 JP 2017175482 A JP2017175482 A JP 2017175482A JP 2017175482 A JP2017175482 A JP 2017175482A JP 2018004657 A5 JP2018004657 A5 JP 2018004657A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- concentration
- avp
- copeptin
- elevated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1210686.0A GB201210686D0 (en) | 2012-06-15 | 2012-06-15 | V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level |
| GB1210686.0 | 2012-06-15 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015516647A Division JP6309511B2 (ja) | 2012-06-15 | 2013-06-17 | 上昇したａｖｐレベルおよび上昇したコペプチンレベルの少なくとも一方を有する患者の治療における使用のためのｖ１ｂ受容体アンタゴニスト |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018004657A JP2018004657A (ja) | 2018-01-11 |
| JP2018004657A5 true JP2018004657A5 (https=) | 2018-04-12 |
| JP6608891B2 JP6608891B2 (ja) | 2019-11-20 |
Family
ID=46641019
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015516647A Active JP6309511B2 (ja) | 2012-06-15 | 2013-06-17 | 上昇したａｖｐレベルおよび上昇したコペプチンレベルの少なくとも一方を有する患者の治療における使用のためのｖ１ｂ受容体アンタゴニスト |
| JP2017175482A Active JP6608891B2 (ja) | 2012-06-15 | 2017-09-13 | うつ症状および不安症状の少なくとも一方を有する患者におけるｖ１ｂ受容体アンタゴニストに対する治療応答を予測する方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015516647A Active JP6309511B2 (ja) | 2012-06-15 | 2013-06-17 | 上昇したａｖｐレベルおよび上昇したコペプチンレベルの少なくとも一方を有する患者の治療における使用のためのｖ１ｂ受容体アンタゴニスト |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20150150846A1 (https=) |
| EP (2) | EP3276010B1 (https=) |
| JP (2) | JP6309511B2 (https=) |
| ES (1) | ES2873926T3 (https=) |
| GB (1) | GB201210686D0 (https=) |
| WO (1) | WO2013186399A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201210686D0 (en) | 2012-06-15 | 2012-08-01 | Holsboermaschmeyer Neurochemie Gmbh | V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level |
| GB201310782D0 (en) | 2013-06-17 | 2013-07-31 | Max Planck Innovation Gmbh | Method for predicting a treatment response to a CRHR1 antagonist and/or V1B antagonist in a patient with depressive and/or anxiety symptoms |
| WO2019099615A1 (en) * | 2017-11-17 | 2019-05-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of copeptin to modulate the immune response and hematopoiesis, and stimulate bone growth |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| EP3915120A1 (en) * | 2019-01-23 | 2021-12-01 | The Regents of the University of Michigan | Pharmacogenomic decision support for modulators of the nmda, glycine, and ampa receptors |
| KR102318236B1 (ko) * | 2020-02-18 | 2021-10-26 | 한림대학교 산학협력단 | 혈중 코펩틴의 농도를 이용한 지연성 뇌허혈 진단 방법 |
| KR20230090589A (ko) * | 2021-12-15 | 2023-06-22 | 국립해양생물자원관 | 성게 유래 펩타이드 및 이의 용도 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR19990067704A (ko) | 1992-12-17 | 1999-08-25 | 디. 제이. 우드, 스피겔 알렌 제이 | 부신피질자극호르몬 유리인자 길항제로서의 피롤로피리미딘을함유하는 약학 조성물 |
| BR9407799A (pt) | 1993-10-12 | 1997-05-06 | Du Pont Merck Pharma | Composição de matéria método de tratamento e composição farmaceutica |
| TW530047B (en) | 1994-06-08 | 2003-05-01 | Pfizer | Corticotropin releasing factor antagonists |
| US5591588A (en) * | 1994-09-20 | 1997-01-07 | Gideon Goldstein | Method for the diagnosis of depression based on monitoring blood levels of arginine vasopressin and/or thymopoietin |
| US6403599B1 (en) | 1995-11-08 | 2002-06-11 | Pfizer Inc | Corticotropin releasing factor antagonists |
| US7067664B1 (en) | 1995-06-06 | 2006-06-27 | Pfizer Inc. | Corticotropin releasing factor antagonists |
| AU713673B2 (en) | 1996-02-07 | 1999-12-09 | Neurocrine Biosciences Inc. | Pyrazolopyrimidines as crf receptor antagonists |
| US6060478A (en) | 1996-07-24 | 2000-05-09 | Dupont Pharmaceuticals | Azolo triazines and pyrimidines |
| HU229024B1 (en) | 1996-07-24 | 2013-07-29 | Bristol Myers Squibb Pharma Co | Azolo-pyridimidines, pharmaceutical compositions containing the same and use thereof |
| FR2796380B3 (fr) | 1999-07-15 | 2001-08-17 | Sanofi Synthelabo | Nouveaux derives d'aminothiazoles, leur preparation et les compositions pharmaceutiques les contenant |
| US20030092019A1 (en) | 2001-01-09 | 2003-05-15 | Millennium Pharmaceuticals, Inc. | Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia |
| NZ528207A (en) | 2001-03-13 | 2006-02-24 | Bristol Myers Squibb Pharma Co | 4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl) pyrazolo-[1,5-A]-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands |
| US20060240419A1 (en) | 2002-05-17 | 2006-10-26 | Yusuke Nakamura | Method of detecting gene polymorphism |
| GR1004664B (en) | 2002-11-26 | 2004-09-02 | Bionature E A Ltd | The charakteristics and advantages of our invention are illustrated by the following description, methods and results of our research, attached figures and supporting references |
| GB0308208D0 (en) | 2003-04-09 | 2003-05-14 | Glaxo Group Ltd | Chemical compounds |
| JP4618127B2 (ja) | 2003-08-28 | 2011-01-26 | 大正製薬株式会社 | １，３−ジヒドロ−２ｈ−インドール−２−オン誘導体 |
| US20050069936A1 (en) | 2003-09-26 | 2005-03-31 | Cornelius Diamond | Diagnostic markers of depression treatment and methods of use thereof |
| JP2008509674A (ja) * | 2004-08-13 | 2008-04-03 | ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | うつ病および不安についての処置応答を決定および予測するための組成物および方法 |
| EP1628136A1 (en) * | 2004-08-19 | 2006-02-22 | B.R.A.H.M.S. Aktiengesellschaft | Method of diagnosis of disease using copeptin |
| GB0519957D0 (en) | 2005-09-30 | 2005-11-09 | Sb Pharmco Inc | Chemical compound |
| CA2593044A1 (en) | 2004-12-31 | 2006-07-13 | Abbott Gmbh & Co. Kg | Substituted oxindole derivatives, medicaments containing said derivatives and use thereof |
| US8030499B2 (en) | 2005-01-28 | 2011-10-04 | Taisho Pharmaceutical Co., Ltd. | 1,3-dihydro-2H-indole-2-one compound and pyrrolidine-2-one compound fused with aromatic heterocycle |
| US20090306137A1 (en) | 2006-05-22 | 2009-12-10 | Wolfgang Curt D | Treatment for depressive disorders |
| UY30846A1 (es) * | 2006-12-30 | 2008-07-31 | Abbott Gmbh & Amp | Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos |
| EP2520670B1 (en) * | 2007-06-12 | 2014-02-26 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | New polymorphisms in ABCB1 associated with a lack of clinical response to medicaments |
| CN102037355A (zh) * | 2008-03-04 | 2011-04-27 | 里奇诊断学股份有限公司 | 基于多重生物标记物板块诊断和监测抑郁症 |
| WO2009113985A1 (en) | 2008-03-13 | 2009-09-17 | Maria Athanasiou | Genetic markers associated with response to antidepressants |
| WO2009130232A1 (en) | 2008-04-24 | 2009-10-29 | Glaxo Group Limited | Pyrazolo [1, 5 -a] pyrazine derivatives as antagonists of v1b receptors |
| WO2011047856A1 (en) | 2009-10-22 | 2011-04-28 | Universiteit Leiden | Disease susceptibility |
| US20150094310A1 (en) | 2012-04-23 | 2015-04-02 | Holsboermaschmeyer Neurochemie Gmbh | Crhr1 antagonists for use in the treatment of patients having crh overactivity |
| US20150278438A1 (en) | 2012-04-23 | 2015-10-01 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Genetic predictors of response to treatment with crhr1 antagonists |
| GB201210686D0 (en) | 2012-06-15 | 2012-08-01 | Holsboermaschmeyer Neurochemie Gmbh | V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level |
| GB201310782D0 (en) | 2013-06-17 | 2013-07-31 | Max Planck Innovation Gmbh | Method for predicting a treatment response to a CRHR1 antagonist and/or V1B antagonist in a patient with depressive and/or anxiety symptoms |
-
2012
- 2012-06-15 GB GBGB1210686.0A patent/GB201210686D0/en not_active Ceased
-
2013
- 2013-06-17 EP EP17168747.8A patent/EP3276010B1/en active Active
- 2013-06-17 US US14/407,594 patent/US20150150846A1/en not_active Abandoned
- 2013-06-17 JP JP2015516647A patent/JP6309511B2/ja active Active
- 2013-06-17 EP EP13729363.5A patent/EP2861253A1/en not_active Withdrawn
- 2013-06-17 WO PCT/EP2013/062552 patent/WO2013186399A1/en not_active Ceased
- 2013-06-17 ES ES17168747T patent/ES2873926T3/es active Active
-
2017
- 2017-09-13 JP JP2017175482A patent/JP6608891B2/ja active Active
- 2017-10-26 US US15/794,520 patent/US20180042898A1/en not_active Abandoned
-
2019
- 2019-08-15 US US16/541,622 patent/US10857129B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018004657A5 (https=) | ||
| Nissen et al. | Soluble CD163 changes indicate monocyte association with cognitive deficits in Parkinson's disease | |
| WO2012106514A3 (en) | System and method for diagnosis and treatment | |
| WO2015006489A8 (en) | Blood-based screen for detecting neurological diseases in primary care settings | |
| EP4234583A3 (en) | Evaluation and treatment of bradykinin-mediated disorders | |
| WO2015031808A3 (en) | Diagnostic methods and compositions for treatment of glioblastoma | |
| Fischer et al. | Assay characteristics influence the aldosterone to renin ratio as a screening tool for primary aldosteronism: results of the German Conn’s registry | |
| WO2017025617A8 (en) | Method for the quantification of faecalibacterium prausnitzii phylogroup i and/or phylogroup ii members and the use thereof as biomarkers | |
| GB2528657A8 (en) | Sample analysing device | |
| JP2014517308A5 (https=) | ||
| MX2022011632A (es) | Anticuerpos contra mucina 17 y usos de los mismos. | |
| JP2017508144A5 (https=) | ||
| JP2011528797A5 (https=) | ||
| WO2015049390A3 (en) | Kidney disease biomarker | |
| WO2017167942A8 (en) | Method for predicting the response of melanoma patients to a medicament | |
| JP2020056595A5 (https=) | ||
| WO2018026969A3 (en) | Plazomicin antibodies and methods of use | |
| JP5695075B2 (ja) | アルツハイマー病又は軽度認知症のバイオマーカー | |
| JP2015528562A5 (https=) | ||
| Freiman et al. | The change in blood glucose level after a moderate stress as a parameter of stress reactivity in anxiety and depression: A pilot translational study | |
| JP2015503106A5 (https=) | ||
| AR097591A1 (es) | Métodos para determinar la respuesta a la terapia | |
| JP2016119915A5 (https=) | ||
| WO2015126922A3 (en) | Rapid phenotype tests for antitubercular drug sensitivity and resistance | |
| MY179665A (en) | In vitro diagnostic method for alzhemer's disease based on the albumin redox level in the cerebrospinal fluid |